AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
COMBINED-MODALITY IN ADVANCED HODGKINS-DISEASE - REPLY
Authors: LOEFFLER M BROSTEANU O HASENCLEVER D
Citation: M. Loeffler et al., COMBINED-MODALITY IN ADVANCED HODGKINS-DISEASE - REPLY, Journal of clinical oncology, 16(8), 1998, pp. 2894-2894
METAANALYSIS OF CHEMOTHERAPY VERSUS COMBINED-MODALITY TREATMENT TRIALS IN HODGKINS-DISEASE
Authors: LOEFFLER M BROSTEANU O HASENCLEVER D SEXTRO M ASSOULINE D BARTOLUCCI AA CASSILETH PA CROWTHER D DIEHL V FISHER RI HOPPE RT JACOBS P PATER JL PAVLOVSKY S THOMPSON E WIERNIK P
Citation: M. Loeffler et al., METAANALYSIS OF CHEMOTHERAPY VERSUS COMBINED-MODALITY TREATMENT TRIALS IN HODGKINS-DISEASE, Journal of clinical oncology, 16(3), 1998, pp. 818-829
REGRESSION WITH BOUNDED OUTCOME SCORE - EVALUATION OF POWER BY BOOTSTRAP AND SIMULATION IN A CHRONIC MYELOGENOUS LEUKEMIA CLINICAL-TRIAL
Authors: TSODIKOV A HASENCLEVER D LOEFFLER M
Citation: A. Tsodikov et al., REGRESSION WITH BOUNDED OUTCOME SCORE - EVALUATION OF POWER BY BOOTSTRAP AND SIMULATION IN A CHRONIC MYELOGENOUS LEUKEMIA CLINICAL-TRIAL, Statistics in medicine, 17(17), 1998, pp. 1909-1922
ALLOGENEIC BONE-MARROW TRANSPLANTATION VERSUS FILGRASTIM-MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PATIENTS WITH EARLY LEUKEMIA
Authors: SCHMITZ N BACIGALUPO A HASENCLEVER D GRATWOHL A
Citation: N. Schmitz et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION VERSUS FILGRASTIM-MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PATIENTS WITH EARLY LEUKEMIA, Bone marrow transplantation, 21, 1998, pp. 34-34
ALLOGENEIC BONE-MARROW TRANSPLANTATION VS FILGRASTIM-MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PATIENTS WITH EARLY LEUKEMIA - FIRST RESULTS OF A RANDOMIZED MULTICENTER TRIAL OF THE EUROPEANGROUP FOR BLOOD AND MARROW TRANSPLANTATION
Authors: SCHMITZ N BACIGALUPO A HASENCLEVER D NAGLER A GLUCKMAN E CLARK P BOURQUELOT P GREINIX H FRICKHOFEN N RINGDEN O ZANDER A APPERLEY JF GORIN C BORKETT K SCHWAB G GOEBEL M RUSSELL NH GRATWOHL A
Citation: N. Schmitz et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION VS FILGRASTIM-MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PATIENTS WITH EARLY LEUKEMIA - FIRST RESULTS OF A RANDOMIZED MULTICENTER TRIAL OF THE EUROPEANGROUP FOR BLOOD AND MARROW TRANSPLANTATION, Bone marrow transplantation, 21(10), 1998, pp. 995-1003
A PROGNOSTIC SCORE FOR ADVANCED HODGKINS-DISEASE
Authors: HASENCLEVER D DIEHL V
Citation: D. Hasenclever et V. Diehl, A PROGNOSTIC SCORE FOR ADVANCED HODGKINS-DISEASE, The New England journal of medicine, 339(21), 1998, pp. 1506-1514
BEACOPP - AN INTENSIFIED CHEMOTHERAPY REGIMEN IN ADVANCED HODGKINS-DISEASE
Authors: DIEHL V SIEBER M RUFFER U LATHAN B HASENCLEVER D PFREUNDSCHUH M LOEFFLER M LIEBERZ D KOCH P ADLER M TESCH H
Citation: V. Diehl et al., BEACOPP - AN INTENSIFIED CHEMOTHERAPY REGIMEN IN ADVANCED HODGKINS-DISEASE, Annals of oncology, 8(2), 1997, pp. 143-148
DOSE-RESPONSE RELATIONSHIP OF COMPLEMENTARY RADIOTHERAPY FOLLOWING 4 CYCLES OF COMBINATION CHEMOTHERAPY IN INTERMEDIATE-STAGE HODGKINS-DISEASE
Authors: LOEFFLER M DIEHL V PFREUNDSCHUH M RUHL U HASENCLEVER D NISTERSBACKES H SIEBER M TESCH H FRANKLIN J GEILEN W BARTELS H CARTONI C DOLKEN G ENZIAN J FUCHS R GASSMANN W GERHARTZ H HAGENAUKAMP U HILLER E HINKELBEIN H HINTERBERGER W KIRCHNER H KOCH P KRUGER B KURTEN H KUTZNER K LOOS U MENDE W MULLER H OERTEL W PETSCH S PFAB R PFLUGER H ROHLOFF R SAUER R SCHALK K SCHICK HD SCHOPPE W SZEPESI S TEICHMANN J WORST P FISCHER R GEORGII A HUBNER K SCHWARZE EW
Citation: M. Loeffler et al., DOSE-RESPONSE RELATIONSHIP OF COMPLEMENTARY RADIOTHERAPY FOLLOWING 4 CYCLES OF COMBINATION CHEMOTHERAPY IN INTERMEDIATE-STAGE HODGKINS-DISEASE, Journal of clinical oncology, 15(6), 1997, pp. 2275-2287
HD-R1 - FIRST RESULTS OF A RANDOMIZED TRIAL COMPARING AGGRESSIVE CHEMOTHERAPY WITH HIGH-DOSE THERAPY (HDT) AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH CHEMOSENSITIVE RELAPSE OF HODGKINS-DISEASE (HD)
Authors: SCHMITZ N SEXTRO M HASENCLEVER D CARELLA A FIEDLER F SCHLIMOK G HOSSFELD DK DIEHL V
Citation: N. Schmitz et al., HD-R1 - FIRST RESULTS OF A RANDOMIZED TRIAL COMPARING AGGRESSIVE CHEMOTHERAPY WITH HIGH-DOSE THERAPY (HDT) AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH CHEMOSENSITIVE RELAPSE OF HODGKINS-DISEASE (HD), Blood, 90(10), 1997, pp. 499-499
LYMPHOCYTE-PREDOMINANT HODGKINS-DISEASE - AN IMMUNOHISTOCHEMICAL ANALYSIS OF 208 REVIEWED HODGKINS-DISEASE CASES FROM THE GERMAN HODGKIN STUDY-GROUP
Authors: VONWASIELEWSKI R WERNER M FISCHER R HANSMANN ML HUBNER K HASENCLEVER D FRANKLIN J SEXTRO M DIEHL V GEORGII A
Citation: R. Vonwasielewski et al., LYMPHOCYTE-PREDOMINANT HODGKINS-DISEASE - AN IMMUNOHISTOCHEMICAL ANALYSIS OF 208 REVIEWED HODGKINS-DISEASE CASES FROM THE GERMAN HODGKIN STUDY-GROUP, The American journal of pathology, 150(3), 1997, pp. 793-803
RATIONALE FOR DOSE-ESCALATION OF FIRST LINE CONVENTIONAL CHEMOTHERAPYIN ADVANCED HODGKINS-DISEASE
Authors: HASENCLEVER D LOEFFLER M DIEHL V
Citation: D. Hasenclever et al., RATIONALE FOR DOSE-ESCALATION OF FIRST LINE CONVENTIONAL CHEMOTHERAPYIN ADVANCED HODGKINS-DISEASE, Annals of oncology, 7, 1996, pp. 95-98
RANDOMIZED TRIAL WITH EARLY-STAGE HODGKINS-DISEASE TESTING 30 GY VS 40 GY EXTENDED FIELD RADIOTHERAPY ALONE
Authors: DUHMKE E DIEHL V LOEFFLER M MUELLER RP RUEHL U WILLICH N GEORGII A ROTH S MATTHAEI D SEHLEN S BROSTEANU O HASENCLEVER D WILKOWSKI R BECKER K
Citation: E. Duhmke et al., RANDOMIZED TRIAL WITH EARLY-STAGE HODGKINS-DISEASE TESTING 30 GY VS 40 GY EXTENDED FIELD RADIOTHERAPY ALONE, International journal of radiation oncology, biology, physics, 36(2), 1996, pp. 305-310
SAFETY OF ALLOPBPCT DONORS - BIOMETRICAL CONSIDERATIONS ON MONITORINGLONG-TERM RISKS
Authors: HASENCLEVER D SEXTRO M
Citation: D. Hasenclever et M. Sextro, SAFETY OF ALLOPBPCT DONORS - BIOMETRICAL CONSIDERATIONS ON MONITORINGLONG-TERM RISKS, Bone marrow transplantation, 17, 1996, pp. 28-30
STAGE IVB AND ANEMIA ARE POOR PROGNOSTIC FACTORS IN ADVANCED STAGES OF HODGKINS-DISEASE - RESULTS OF THE HD6 STUDY OF THE GHSG
Authors: TESCH H PAULUS U HASENCLEVER D LIEBERZ D SEXTRO M SIEBER M RUEFFER U ENGERT A KOCH T DUEHMKE E GEORGII A LOEFFLER M PFREUNDSCHUH M DIEHL V
Citation: H. Tesch et al., STAGE IVB AND ANEMIA ARE POOR PROGNOSTIC FACTORS IN ADVANCED STAGES OF HODGKINS-DISEASE - RESULTS OF THE HD6 STUDY OF THE GHSG, Blood, 88(10), 1996, pp. 3506-3506
COMBINED-MODALITY TREATMENT VS CHEMOTHERAPY ALONE IN HODGKINS-DISEASE(HD) - AN OVERVIEW ON RANDOMIZED TRIALS
Authors: LOEFFLER M BROSTEANU O HASENCLEVER D SEXTRO M COSSET J DAHLBERG S FISHER R GRAY R HENRYAMAR M HOPPE R SOMERS R SPECHT L
Citation: M. Loeffler et al., COMBINED-MODALITY TREATMENT VS CHEMOTHERAPY ALONE IN HODGKINS-DISEASE(HD) - AN OVERVIEW ON RANDOMIZED TRIALS, Blood, 88(10), 1996, pp. 353-353
THE RAPIDLY ALTERNATING SCHEME COPP-ABV-IMEP IS EQUALLY EFFECTIVE AS COPP-ABVD IN ADVANCED STAGES OF HODGKINS-DISEASE - RESULTS OF THE HD6 STUDY OF THE GHSG
Authors: TESCH H PAULUS U HASENCLEVER D LIEBERZ D SEXTRO M SIEBER M RUEFFER U ENGERT A KOCH T DUEHMKE E GEORGII A LOEFFLER M PFREUNDSCHUH M DIEHL V
Citation: H. Tesch et al., THE RAPIDLY ALTERNATING SCHEME COPP-ABV-IMEP IS EQUALLY EFFECTIVE AS COPP-ABVD IN ADVANCED STAGES OF HODGKINS-DISEASE - RESULTS OF THE HD6 STUDY OF THE GHSG, Blood, 88(10), 1996, pp. 357-357
A NUMERICAL INDEX TO PREDICT TUMOR-CONTROL IN ADVANCED HODGKINS-DISEASE
Authors: HASENCLEVER D DIEHL V
Citation: D. Hasenclever et V. Diehl, A NUMERICAL INDEX TO PREDICT TUMOR-CONTROL IN ADVANCED HODGKINS-DISEASE, Blood, 88(10), 1996, pp. 2680-2680
ESCALATION OF DOSE INTENSITY FOR ADVANCED-STAGE HODGKINS-DISEASE USING THE BEACOPP SCHEME - STUDIES OF THE GERMAN HODGKIN STUDY-GROUP (GHSG)
Authors: TESCH H LATHAN B RUFFER U SIEBER M ENGERT A FRANKLIN J HASENCLEVER D PFREUNDSCHUH M KOCH P ADLER M MULLER U SCHALK P DOLKEN G WORST P BOISSEVAIN F DIEHL V
Citation: H. Tesch et al., ESCALATION OF DOSE INTENSITY FOR ADVANCED-STAGE HODGKINS-DISEASE USING THE BEACOPP SCHEME - STUDIES OF THE GERMAN HODGKIN STUDY-GROUP (GHSG), Blood, 88(10), 1996, pp. 2682-2682
IS THERE A RATIONALE FOR HIGH-DOSE CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED HODGKINS-DISEASE
Authors: HASENCLEVER D SCHMITZ N DIEHL V
Citation: D. Hasenclever et al., IS THERE A RATIONALE FOR HIGH-DOSE CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED HODGKINS-DISEASE, Leukemia & lymphoma, 15, 1995, pp. 47-49
FURTHER CHEMOTHERAPY VERSUS LOW-DOSE INVOLVED-FIELD RADIOTHERAPY AS CONSOLIDATION OF COMPLETE REMISSION AFTER 6 CYCLES OF ALTERNATING CHEMOTHERAPY IN PATIENTS WITH ADVANCED HODGKINS-DISEASE
Authors: DIEHL V LOEFFLER M PFREUNDSCHUH M RUEHL U HASENCLEVER D NISTERSBACKES H SIEBER M SMITH K TESCH H GEILEN W ADLER M BARTELS H BRANDENBURG U DIEZLER P DOELKEN G ENZIAN J FUCHS R GASSMANN W GERHARTZ H HAGENAUKAMP U HECHT T HILLER E HINKELBEIN H LATHAN B KIRCHNER H KUEHN G KUERTEN H LOOS U MAKOSKI B OERTEL W PETSCH S PFAB R PFLUEGER H PLANKER M ROHLOFF R SACK H SAMANDARI S SAUER R SCHALK K SCHMITZ G SCHOPPE W SCHWIEDER G SZEPESI S TEICHMANN J WILHELMY W WORST P FISCHER R GEORGII A HUEBNER K SCHWARZE EW
Citation: V. Diehl et al., FURTHER CHEMOTHERAPY VERSUS LOW-DOSE INVOLVED-FIELD RADIOTHERAPY AS CONSOLIDATION OF COMPLETE REMISSION AFTER 6 CYCLES OF ALTERNATING CHEMOTHERAPY IN PATIENTS WITH ADVANCED HODGKINS-DISEASE, Annals of oncology, 6(9), 1995, pp. 901-910
SERUM CYTOKINE LEVELS CORRELATE WITH CLINICAL-PARAMETERS IN HODGKINS-DISEASE
Authors: GORSCHLUTER M BOHLEN H HASENCLEVER D DIEHL V TESCH H
Citation: M. Gorschluter et al., SERUM CYTOKINE LEVELS CORRELATE WITH CLINICAL-PARAMETERS IN HODGKINS-DISEASE, Annals of oncology, 6(5), 1995, pp. 477-482
BONE-MARROW INVOLVEMENT IN HODGKINS-DISEASE - AN ANALYSIS OF 135 CONSECUTIVE CASES
Authors: MUNKER R HASENCLEVER D BROSTEANU O HILLER E DIEHL V
Citation: R. Munker et al., BONE-MARROW INVOLVEMENT IN HODGKINS-DISEASE - AN ANALYSIS OF 135 CONSECUTIVE CASES, Journal of clinical oncology, 13(2), 1995, pp. 403-409
PARTICIPATION IN MULTICENTER STUDIES AS QUALITY-CONTROL IN THERAPY OFHODGKINS-DISEASE - AN INTERIM-REPORT
Authors: LOHRI A LEYVRAZ S CERNY T HESS U HONEGGER HP GREINER R CASTIGLIONE M HERRMANN R LOFFLER M HASENCLEVER D DIEHL V
Citation: A. Lohri et al., PARTICIPATION IN MULTICENTER STUDIES AS QUALITY-CONTROL IN THERAPY OFHODGKINS-DISEASE - AN INTERIM-REPORT, Schweizerische medizinische Wochenschrift, 125(6), 1995, pp. 217-224
DOSE-ESCALATION FOR ADVANCED-STAGE HODGKINS-DISEASE USING THE BEACOPPSCHEME - STUDIES OF THE GERMAN HODGKIN STUDY-GROUP (GHSG)
Authors: TESCH H LATHAN B HASENCLEVER D RUFFER U SIEBER M ENGERT A PFREUNDSCHUH M KOCH P ADLER M MULLER U SCHALK P DOLKEN G WORST P BOISSEVAIN F LOFFLER M DIEHL V
Citation: H. Tesch et al., DOSE-ESCALATION FOR ADVANCED-STAGE HODGKINS-DISEASE USING THE BEACOPPSCHEME - STUDIES OF THE GERMAN HODGKIN STUDY-GROUP (GHSG), Blood, 86(10), 1995, pp. 1741-1741
EARLY HIGH-DOSE THERAPY TO CONSOLIDATE PATIENTS WITH HIGH-RISK HODGKINS-DISEASE IN FIRST COMPLETE REMISSION - RESULTS OF AN EBMT GHSG MATCHED-PAIR ANALYSIS/
Authors: SCHMITZ N HASENCLEVER D BROSTEANU O CARELLA A COLOMBAT P PROCTOR S LEGROS M BRADLEY S PEARCE R DIEHL V GOLDSTONE AH
Citation: N. Schmitz et al., EARLY HIGH-DOSE THERAPY TO CONSOLIDATE PATIENTS WITH HIGH-RISK HODGKINS-DISEASE IN FIRST COMPLETE REMISSION - RESULTS OF AN EBMT GHSG MATCHED-PAIR ANALYSIS/, Blood, 86(10), 1995, pp. 1742-1742
Risultati: 1-25 | 26-30